3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Head and Neck Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Bile Duct Neoplasms
1
Appendiceal Neoplasms
1
Interventions
pembrolizumab
3
Trastuzumab
2
Interleukin-12 Subunit p35
2
Drug Therapy
2
tivozanib
1
tipifarnib
1
spartalizumab
1
seribantumab
1
pertuzumab
1
motexafin lutetium
1
irinotecan sucrosofate
1
entinostat
1
atezolizumab
1
Specimen Handling
1
Ritonavir
1
Quality of Life
1
Positron Emission Tomography Computed Tomography
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Ondansetron
1
Octreotide
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
irinotecan sucrosofate
×
Gynecologic
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled